Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
Apr 14, 2026, 17:23

Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026

Meghanath Yenni, Consultant Physician at Medicover Hospitals, shared a post on LinkedIn:

”What’s New in Acute Ischemic Stroke – 2026:

Tenecteplase is now first-line – equal to alteplase, with simpler bolus dosing improving real-world speed and logistics.

Treat disability, not NIHSS – even low scores need thrombolysis if the deficit is functionally significant.

Do not delay IVT for extra imaging – give thrombolysis immediately if eligible within 4.5 hours.

Late-window IVT is now viable – selected patients (4.5–9h or wake-up stroke) can be treated using imaging selection.

Avoid thrombolysis in mild non-disabling stroke – prefer short-term DAPT instead.

No role for adjunct antithrombotics with IVT – adding agents like argatroban or eptifibatide offers no benefit.

EVT expands to large-core strokes (ASPECTS 3–5) – now Class 1 in selected patients.

Very large cores (ASPECTS 0–2) are not absolute exclusions – EVT may still be reasonable early.

Pre-stroke disability is no longer a strict barrier – selected mRS of 2 or higher patients can still benefit from EVT.

Basilar artery occlusion now has clear EVT indication – strong recommendation up to 24 hours.

Aggressive BP lowering post-EVT is harmful – avoid targeting SBP less than after successful recanalization.

After IVT, lower BP targets don’t help – less than 180 mmHg remains appropriate, not less than 140.

Tight glucose control is out – intensive insulin targets increase harm without improving outcomes.

Stroke routing is system-dependent – optimize workflow rather than blindly bypassing to EVT centers.

Mobile Stroke Units are endorsed – prehospital thrombolysis improves time-to-treatment and outcomes.

Short-term DAPT (21 days) is standard in minor stroke/TIA – reduces early recurrence risk.

Earlier anticoagulation in AF stroke is reasonable – prevents recurrence with careful patient selection.

Swallow therapy advances but neuroprotection fails – PES may help dysphagia; IV glibenclamide is not recommended.

Source:

2026 Guideline for the Early Management of Acute Ischemic Stroke – Stroke, American Heart Association / American Stroke Association (AHA/ASA).”

Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026

Stay updated with Hemostasis Today.